Multicenter Trial of Prednisone in Alzheimer's Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized placebo controlled, double blind study. Patients who meet eligibility
criteria and decide to participate in the study will be randomly assigned to receive either
drug treatment or a placebo. Neither the patients nor the participating investigators will
know who is receiving the drugs and who is receiving the placebo. Participation involves 15
outpatient clinic visits over a 68 week period. Patients take study medication at varying
doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.